Biodesix, Inc

Biodesix on Yhdysvalloissa toimiva diagnoosiratkaisuihin keskittyvä yritys, joka painottaa keuhkosairauksien testauksia ja diagnostisen kehityksen palveluja. Ydinliiketoiminta yhdistää veripohjaiset kliiniset testit lääkäreille sekä sopimuskehityksen, testauksen ja konsultointipalvelut biolääke-, life sciences- ja akateemisille asiakkaille. Yritys hyödyntää multi-omisia menetelmiä, mukaan lukien genomikka, proteomiikka, radiomiikka ja tekoäly, kehittääkseen ja kaupallistaakseen testejä, jotka vastaavat välittömiin kliinisiin kysymyksiin. Liikevaihto jakautuu Lung Diagnostic Testingin ja Development Servicesin välillä, ja kliininen testaus on suurempi ja vakiintuneempi liiketoiminta.

−25,1 %

−39,8 %

+24,1 %

1.86

1.86

— Biodesix, Inc
%
Lung Diagnostic Testing84% Blood-based diagnostic tests used by healthcare providers to assess lung nodules and related clinical questions.
Development Services16% Custom diagnostic development, testing, and consulting services for biopharma, life sciences, and research partners.

Biodesix myy ensisijaisesti terveydenhuollon palveluntarjoajille ja kliinikoille, jotka tilaavat keuhkodiagnostiikkatestejä potilaille, joilla on...

  • Healthcare providers and cliniciansprimary

    Order blood-based lung diagnostic tests to help assess pulmonary nodules and improve patient management decisions.

  • Biopharmaceutical companiesprimary

    Buy development services, clinical trial sample testing, and biomarker/companion diagnostic support to advance drug and diagnostic programs.

  • Life sciences and diagnostic companiessecondary

    Use Biodesix for assay development, validation, and commercialization support when they need specialized diagnostic capabilities.

  • Academic and research institutionssecondary

    Engage the company for translational research, custom testing, and collaborative discovery work.

  • Payers and reimbursement ecosystemsecondary

    Not direct buyers in the usual sense, but critical to test adoption because coverage and reimbursement determine access and realized revenue.

Biodesixin pääkonttori sijaitsee Yhdysvalloissa ja sen kaupallinen liiketoiminta keskittyy Yhdysvaltain terveydenhuoltomarkkinaan...

  • •Headquartered in the United States
  • •Clinical testing revenue is primarily tied to U.S. physicians and payers
  • •Development Services are marketed to U.S. and international customers
  • •Medicare and Medicaid policy are important to revenue realization
  • •No country-level revenue split was disclosed in the excerpts
  • •U.S. regulatory and reimbursement changes can affect adoption and collections

Biodesix pyrkii laajentamaan keuhkodiagnostiikkatestien käyttöä lisäämällä kliinistä näyttöä ja korvauskattavuutta...

01
Expand lung test adoption and reimbursement

Clinical volume and payer coverage directly drive realized revenue and determine whether the core testing business can scale.

02
Improve operating efficiency and gross margin

Higher test volume only creates durable value if the company can lower cost per test and convert scale into operating leverage.

03
Grow Development Services and strategic partnerships

Biopharma and research relationships diversify revenue and can create longer-term opportunities in companion diagnostics and discovery.

Biodesix on voimakkaasti riippuvainen maksajapolitiikasta, korvauksista ja lääkärien hyväksynnästä, joten markkinahyväksynnän hidastuminen voi...

high

Coverage and reimbursement uncertainty

Diagnostic revenue depends on payer decisions, and the company recognizes lung test revenue using estimates of amounts ultimately collectible.

Scope
Lung Diagnostic Testing
Materiality
high
high

Dependence on Medicare, Medicaid, and federal healthcare programs

A prolonged government shutdown or policy change could delay payments, coverage decisions, or patient access.

Scope
U.S. clinical testing revenue
Materiality
high
high

Commercial adoption risk

Revenue growth depends on physicians, payers, and patients accepting the clinical utility of the tests.

Scope
Nodify Lung and other diagnostic tests
Materiality
high
medium

Biopharma customer retention and expansion

Development Services growth depends on maintaining and expanding relationships with existing customers and winning new ones.

Scope
Development Services
Materiality
medium
medium

Supply chain and single-source supplier dependence

Laboratory testing operations can be disrupted by shortages, price increases, or vendor failures.

Scope
Testing operations and specimen logistics
Materiality
medium
medium

Nasdaq listing compliance

Failure to maintain minimum bid price or other listing standards could affect market access and investor confidence.

Scope
Capital markets access
Materiality
medium
Revenue recognition for lung diagnostic tests
Can materially affect reported revenue, receivables, and margins
ASC 606 contract accounting for Development Services
Can shift revenue between quarters
Variable consideration and collection estimates
Affects revenue, bad debt-like adjustments, and comparability
Share-based compensation
Affects operating expense and net loss

BIODESIX INC

BDSX · Services-Medical Laboratories

DYADIC INTERNATIONAL INC

DYAI · Biological Products, (No Diagnostic Substances)

BIOTRICITY INC.

BTCY · Surgical & Medical Instruments & Apparatus

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

BiomX Inc.

PHGE · Biological Products, (No Diagnostic Substances)

Evofem Biosciences, Inc.

EVFM · Pharmaceutical Preparations

: 11.8.2026